FDA Approves Opdivo, Yervoy Combination For Kidney Cancer | Latest News RSS feed

FDA Approves Opdivo, Yervoy Combination For Kidney Cancer - Latest News


BMS files Opdivo/Yervoy combo for lung cancer

“Lung cancer ... the FDA on the application is expected by February 20 next year. US regulators cleared a combination of Opdivo and Yervoy as a first-line treatment for patients with advanced renal ce... read more

Bristol-Myers Squibb’s immuno-oncology combo therapy, Opdivo receives US FDA approval for colorectal cancer

Bristol-Myers Squibb Company announced that its Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy (ipilimumab ... of the study at USC Norris Comprehensive Cancer Center. “The FDA’s approval of an I-O/I- ... read more

FDA OKs Bristol-Myers' Opdivo + Yervoy for first-line kidney cancer

The FDA approves Bristol-Myers Squibb's (BMY-8.4%) combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for the first-line treatment of patients with intermediate- and poor-risk advanced renal ce... read more

Looking for another news?


Combinations Poised to Carry Clinical Benefit in RCC

Combination therapies have become a standard of care in advanced renal cell carcinoma (RCC) in the United States following the FDA approval of nivolumab (Opdivo) and ipilimumab ... When we look at kid... read more


Pfizer/Merck KGaA eye fast review for kidney cancer combo

Earlier this year the FDA approved Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab) combination in untreated patients with intermediate or poor risk of advanced renal cell ... read more

FDA approves Bristol-Myers drug for new use in kidney cancer

The FDA first approved Opdivo for melanoma last December. Opdivo is part of a new class of drugs that work by blocking a protein that prevents the body's immune system from attacking cancer cells. Sim... read more

BMS’ Opdivo/Yervoy combo cleared for kidney cancer

US regulators have approved a combination of Bristol-Myers Squibb ... patients across PD-L1 expression levels.” Lung cancer success Meanwhile, BMS also unveiled new data showing that the Opdivo/Yervoy ... read more

Cancer Space Update: FDA Approves Label Expansion of 4 Drugs

The combination therapy is currently being evaluated in a phase Ib study. Exelixis' Cabometyx Approved in First-Line Kidney Cancer: Exelixis’s RCC drug, Cabometyx, was granted label expansion in first ... read more

FDA accepts Bristol-Myers' marketing application for Opdivo/Yervoy for intermediate/poor-risk kidney cancer

The FDA accepts for review Bristol-Myers Squibb's (NYSE:BMY) marketing application seeking approval for the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) to treat intermediate- and poor-ri... read more

U.S. FDA approves Bristol-Myers' Opdivo for bladder cancer

kidney cancer, and Hodgkin lymphoma. Investors were disappointed last month when Bristol-Myers said it would not seek accelerated FDA approval for a combination of Opdivo and another immunotherapy, Ye... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us